18F-DCFPyL Positron Emission Tomography (PET)/Computed Tomography (CT) in Men With Prostate Cancer
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 129
- 试验地点
- 1
- 主要终点
- To determine the positive predictive value of 18F-DCFPyL PET/CT on a per-patient basis
研究概览
简要总结
PyL, also known as [18F]DCFPyL, is a second-generation fluorinated prostate-specific membrane antigen (PSMA) targeted PET imaging agent. In preliminary studies it demonstrates a higher detection of metastatic prostate lesions compared to standard imaging. Its ability to image metastatic prostate cancer sites was comparable to 68Ga-PSMA with high tumor-to-background ratios.Additionally, [18F] PyL demonstrated higher mean tumor-to-background ratios when using kidney, spleen, or parotid as reference organs. However, the role of [18F] PyL in tumor response to therapy has not been evaluated, specifically the potential to serve as a predictive biomarker of response. Given the high cost of current therapeutic agents in mCRPC, there is a need for an early response biomarker to stratify which patients will benefit from therapy and which will not. This will also allow for earlier change in management of patients who will not response to these therapies, potentially improving patient outcomes.
详细描述
The investigators will conduct a prospective phase II/III study of 300 men diagnosed with prostate cancer with a rising prostate-specific antigen (PSA). Upon enrollment, subjects will undergo standard of care imaging (defined as a CT or MRI of the chest, abdomen, and pelvis, and 99mTc bone scans) if not obtained within 45 days of enrollment. Subjects will have standard of care laboratory evaluations and undergo 18F- DCFPyL PET/CT.
[18F]DCFPyL will be used for study imaging.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed diagnosis of prostate cancer
- •PSA ≥ 0.2ng/ml
- •Age ≥ 18 years of age
- •Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (karnofsky ≥ 60%)
- •Ability to understand and willingness to sign a written informed consent document
- •Wiling to comply with clinical trial instructions and requirements
- •Willing to cover the cost of PyL PET/CT imaging if funds are not available
排除标准
- •History of another active malignancy within 3 years, other than basal cell and squamous cell carcinoma of the skin
- •Presence of prostate brachytherapy implants unless approved by the PI
- •Administration of another radioisotope within five physical half-lives of trial enrollment
- •Radiation or chemotherapy within 2 weeks prior to trial enrollment
- •Serum creatinine > 3 times the upper limit of normal
- •Serum total bilirubin > 3 times the upper limit of normal
- •Aspartate transaminase (AST) or alanine aminotransferase (ALT) >5 times the upper limit of normal
- •Inadequate venous access
研究组 & 干预措施
18F- DCFPyL PET/CT
Upon enrollment, subjects will undergo standard of care imaging (defined as a CT or MRI of the chest, abdomen, and pelvis, and 99mTc bone scans) if not obtained within 45 days of enrollment. Subjects will have standard of care laboratory evaluations including complete blood count (CBC), serum chemistries, hepatic panel, lactate dehydrogenase (LDH), and PSA. Liquid biopsies for circulating tumor DNA (ctDNA) and exosome analysis will occur at the same time. Subjects will then undergo 18F- DCFPyL PET/CT.
干预措施: 18F- DCFPyL PET/CT (Drug)
结局指标
主要结局
To determine the positive predictive value of 18F-DCFPyL PET/CT on a per-patient basis
时间窗: 3.5 years
To determine the positive predictive value of 18F-DCFPyL PET/CT on a per-patient basis
次要结局
- To determine the positive predictive value of 18F-DCFPyL PET/CT on a per-region basis, with regions being the prostate or prostate bed, pelvis, extra pelvis, and bones(3.5 years)
- To determine the sensitivity and specificity of 18F-DCFPyL PET/CT on a per patient and region basis(3.5 years)
研究者
Matthew Dallos
Associate Clinical Professor of Medicine
Columbia University